Drug: Nyvepria (pegfilgrastim-apgf)

Manufacturer: Pfizer

Route of Administration: Subcutaneous

Site of Care: Outpatient

Approved Indication: to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia

Disease: neutropenia associated with myelosuppressive anti-cancer therapy

Therapeutic Area: Hematology, Oncology

Enrollment Form Link: Pfizer Oncology together

Phone Number: 1-877-744-5675

Fax Number: N/A

Product Website: nyvepria.com